Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Orbifloxacin is a synthetic, broad-spectrum fluoroquinolone antibiotic used exclusively in veterinary medicine. It is primarily indicated for the treatment of bacterial infections in dogs and cats, including urinary tract infections (cystitis), skin and soft tissue infections (such as wounds and abscesses), and respiratory tract infections caused by susceptible organisms. Orbifloxacin acts by inhibiting bacterial DNA gyrase, an enzyme essential for DNA replication, transcription, repair, and recombination. This disruption prevents bacteria from multiplying and leads to cell death. The drug is bactericidal against a wide range of gram-negative and gram-positive organisms[1][3][4][5][6]. It is not approved for use in food-producing animals. Developers: Schering-Plough Animal Health Manufacturers: Merck Animal Health
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on orbifloxacin.